A brief report with an overview of key developments in the field of market access for medical devices and in-vitro diagnostic tests in 2020 and anticipated developments in 2021 in Europe
In January 2021, we performed the first annual survey of our customers to synch with our internal knowledge about key developments in the area of market access in European countries.
Our team maintains a good level of understanding of reimbursement processes via routine monitoring of reimbursement systems via our Reimbursement and HTA Alerts services, project work, interviews, and engagement with the clients.
This year, we have decided to ask our clients about their understanding of the key developments of reimbursement systems in 2020 and anticipated changes in 2021. This report provides a brief summary of key internal findings and information obtained from the participants of the survey.
The year 2020 was shaped by the COVID-19 crisis, and it led to a pause on elective procedures, growth of waiting lists, introduction of reimbursement for remote consultations in some countries (e.g., in Belgium and the Netherlands), and delayed capital investments. But COVID-related crisis did not lead to any conceptual changes of the reimbursement frameworks. Therefore, we will not be focusing on them in this report.
There are several key trends that we want to acknowledge in this report:
Some areas remained without significant development, for example, HTA frameworks in most countries.
The report presents developments in Belgium, Denmark, England, France, Germany, the Netherlands, Norway, Russia, Sweden and Switzerland
This is a brief report with only mentioning of key developments in 2020 and anticipated developments in 2021
The report only focuses on developments in the med tech field. The situation with pharmaceuticals is not considered
For each country, a brief statement about developments in 2020 and expected changes in 2021 is provided